GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for brain cancer patients: experimental combo targets glioblastoma
Disease control Recruiting nowThis study tests a new drug, Debio 0123, combined with standard chemotherapy (temozolomide) and sometimes radiation for adults with glioblastoma, a fast-growing brain tumor. The goal is to find the safest dose and see if the combination helps people live longer. About 116 partici…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated May 26, 2026 09:06 UTC
-
New drug targets deadly brain cancer in early trial
Disease control Recruiting nowThis study tests a new drug called LMP744 in 40 adults whose glioblastoma (a type of brain cancer) has come back after standard treatment. The drug is given through a vein for 5 days each month for up to a year. The goal is to see if it can shrink tumors or slow their growth.
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated May 26, 2026 08:56 UTC